Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery.

Oncogene - 15 Aug 2013

Sampson E R, McMurray H R, Hassane D C, Newman L, Salzman P, Jordan C T, Land H

Abstract excerpt

Malignant cell transformation commonly results in the deregulation of thousands of cellular genes, an observation that suggests a complex biological process and an inherently challenging scenario for the development of effective cancer interventions. To better define the genes/pathways essential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Blotting, Western
Share to Chromatin Immunoprecipitation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Mice, Nude

Share to Neoplasms, Experimental

Share to Real-Time Polymerase Chain Reaction

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 22964631
DOI: 10.1038/onc.2012.389
PMCID: PMC3631583

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22964631-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery.PMID 22964631Read ↗

Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype.Semantic proximity Read ↗

Perturbational Gene-Expression Signatures for Combinatorial Drug DiscoverySemantic proximity Read ↗

Cancer gene expression signatures - the rise and fall?Semantic proximity Read ↗

Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signatureSemantic proximity Read ↗

Cooperative genomic alteration network reveals molecular classification across 12 major cancer types.Semantic proximity Read ↗

Systematic identification of combinatorial drivers and targets in cancer cell lines.Semantic proximity Read ↗

Functional synergies yet distinct modulators affected by genetic alterations in common human cancers.Semantic proximity Read ↗

Widespread genetic epistasis among cancer genes.Semantic proximity Read ↗

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors.Semantic proximity Read ↗

Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanismsSemantic proximity Read ↗

Exploiting convergent evolution to derive a pan-cancer cisplatin response gene expression signatureSemantic proximity Read ↗

Functional genomics reveals an off-target dependency of drug synergy in gastric cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.